Immunotherapy With or Without Chemotherapy in Advanced NSCLC-A Delicate Balance of Harm and Benefit. - Suppr | 超能文献

Immunotherapy With or Without Chemotherapy in Advanced NSCLC-A Delicate Balance of Harm and Benefit.

作者信息

Mountzios Giannis

机构信息

Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.

出版信息

JAMA Oncol. 2025 Jul 1;11(7):716-717. doi: 10.1001/jamaoncol.2025.0897.

DOI:10.1001/jamaoncol.2025.0897

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Immunotherapy With or Without Chemotherapy in Advanced NSCLC-A Delicate Balance of Harm and Benefit.

JAMA Oncol. 2025 Jul 1;11(7):716-717. doi: 10.1001/jamaoncol.2025.0897.

2

Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.老年非小细胞肺癌且程序性死亡受体配体1（PD-L1）低表达患者接受化疗联合或不联合免疫治疗的疗效

Transl Lung Cancer Res. 2025 May 30;14(5):1558-1568. doi: 10.21037/tlcr-2024-1236. Epub 2025 May 22.

3

Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis.一线免疫治疗联合方案治疗晚期 NSCLC 的疗效和安全性：系统评价和网络荟萃分析。

J Thorac Oncol. 2021 Jul;16(7):1099-1117. doi: 10.1016/j.jtho.2021.03.016. Epub 2021 Apr 8.

4

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.一线纳武利尤单抗联合基于伊匹木单抗的治疗方案用于肿瘤程序性死亡配体1低于1%的转移性非小细胞肺癌患者的长期生存结果：一项汇总分析

J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4.

5

Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer.化疗联合贝伐单抗加或不加免疫疗法作为结直肠癌一线治疗的真实世界比较

World J Gastroenterol. 2025 Jun 28;31(24):108298. doi: 10.3748/wjg.v31.i24.108298.

6

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.免疫检查点抑制剂治疗有无 PD-L1 选择的晚期非小细胞肺癌的疗效和安全性：系统评价和网络荟萃分析。

Chin Med J (Engl). 2023 Sep 20;136(18):2156-2165. doi: 10.1097/CM9.0000000000002750. Epub 2023 Aug 18.

7

Chemotherapy for advanced gastric cancer.晚期胃癌的化疗

Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4.

8

Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.中危非肌层浸润性膀胱癌患者的膀胱内治疗：疾病复发的系统评价和网络荟萃分析。

Eur Urol Focus. 2022 Mar;8(2):447-456. doi: 10.1016/j.euf.2021.03.016. Epub 2021 Mar 21.

9

Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis.在晚期转移性三阴性乳腺癌中确定从PD-1检查点抑制联合化疗中获益最大的亚组：一项系统评价和荟萃分析

World J Surg Oncol. 2024 Dec 21;22(1):346. doi: 10.1186/s12957-024-03424-3.

10

Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.免疫检查点抑制剂联合铂类化疗对比铂类化疗联合或不联合贝伐珠单抗用于治疗老年人晚期非小细胞肺癌的一线治疗。

Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495.

引用本文的文献

1

Liposomal Doxorubicin, but Not Platinum-Taxane, Supports MHC-II Expression and Immune Maturation in the Ovarian Tumor Microenvironment.脂质体阿霉素而非铂类紫杉烷制剂可支持卵巢肿瘤微环境中的MHC-II表达和免疫成熟。

Cancers (Basel). 2025 Aug 29;17(17):2827. doi: 10.3390/cancers17172827.